,Maryville NURS 615 Exam 1 | Advanced
Pharmacotherapeutics (2026) Q&A
1. The point in time on the drug concentration curve that indicates the first sign of a
therapeutic effect is the:
A) Minimum adverse effect level
B) Onset of action
C) Duration of action
D) Therapeutic range
Correct Answer: Onset of action
Rationale: Onset of action is the time required for a drug to begin producing a
therapeutic effect after administration. The minimum adverse effect level is the dose
at which side effects begin to appear, duration of action is how long the drug
remains effective, and therapeutic range is the window between the minimum
effective concentration and the minimum toxic concentration.
2. Nurse practitioner prescriptive authority is regulated by:
A) The Drug Enforcement Administration (DEA)
B) The State Board of Nursing
C) The Food and Drug Administration (FDA)
D) The individual state's Nurse Practice Act
Correct Answer: The individual state's Nurse Practice Act
,Rationale: Nurse practitioner prescriptive authority is regulated by the individual
state's Nurse Practice Act, which defines the scope of practice, including prescribing
privileges, for advanced practice nurses in that state.
3. A patient with chronic kidney disease (CKD) is prescribed a drug that is primarily
renally excreted. The provider should anticipate which adjustment?
A) Increasing the dose to achieve therapeutic effect
B) Decreasing the dose or increasing the dosing interval
C) No change in dosing
D) Switching to a drug with a shorter half-life
Correct Answer: Decreasing the dose or increasing the dosing interval
Rationale: In CKD, renal excretion is impaired, leading to drug accumulation.
Therefore, a dose reduction or an extended dosing interval is typically required to
prevent toxicity. The dose should be adjusted based on the patient's glomerular
filtration rate (GFR).
4. How does hypoalbuminemia affect the process of prescribing?
A) It decreases the free drug concentration, requiring a higher dose
B) It increases the free drug concentration, potentially leading to toxicity
C) It has no effect on drug binding
D) It decreases drug metabolism
Correct Answer: It increases the free drug concentration, potentially leading to
toxicity
Rationale: Hypoalbuminemia reduces the number of protein-binding sites available
for highly protein-bound drugs. This results in a higher fraction of unbound (free)
, drug, which is pharmacologically active, increasing the risk of toxicity and requiring a
lower dose.
5. A patient with a CYP2C19 mutation is prescribed a medication metabolized by this
enzyme. What is the most likely outcome?
A) Increased drug efficacy
B) Increased risk of adverse effects or decreased efficacy depending on the mutation
type
C) No change in drug response
D) Immediate allergic reaction
Correct Answer: Increased risk of adverse effects or decreased efficacy depending
on the mutation type
Rationale: CYP2C19 polymorphisms can result in poor, intermediate, or rapid
metabolizer phenotypes. Poor metabolizers are at risk for toxicity, while rapid
metabolizers may experience therapeutic failure. Genetic testing can guide dosing to
optimize therapy and minimize adverse effects.
6. Which drug is known to auto-induce its own metabolism, requiring careful
monitoring and dose adjustments over time?
A) Warfarin
B) Carbamazepine
C) Levothyroxine
D) Metformin
Correct Answer: Carbamazepine
Pharmacotherapeutics (2026) Q&A
1. The point in time on the drug concentration curve that indicates the first sign of a
therapeutic effect is the:
A) Minimum adverse effect level
B) Onset of action
C) Duration of action
D) Therapeutic range
Correct Answer: Onset of action
Rationale: Onset of action is the time required for a drug to begin producing a
therapeutic effect after administration. The minimum adverse effect level is the dose
at which side effects begin to appear, duration of action is how long the drug
remains effective, and therapeutic range is the window between the minimum
effective concentration and the minimum toxic concentration.
2. Nurse practitioner prescriptive authority is regulated by:
A) The Drug Enforcement Administration (DEA)
B) The State Board of Nursing
C) The Food and Drug Administration (FDA)
D) The individual state's Nurse Practice Act
Correct Answer: The individual state's Nurse Practice Act
,Rationale: Nurse practitioner prescriptive authority is regulated by the individual
state's Nurse Practice Act, which defines the scope of practice, including prescribing
privileges, for advanced practice nurses in that state.
3. A patient with chronic kidney disease (CKD) is prescribed a drug that is primarily
renally excreted. The provider should anticipate which adjustment?
A) Increasing the dose to achieve therapeutic effect
B) Decreasing the dose or increasing the dosing interval
C) No change in dosing
D) Switching to a drug with a shorter half-life
Correct Answer: Decreasing the dose or increasing the dosing interval
Rationale: In CKD, renal excretion is impaired, leading to drug accumulation.
Therefore, a dose reduction or an extended dosing interval is typically required to
prevent toxicity. The dose should be adjusted based on the patient's glomerular
filtration rate (GFR).
4. How does hypoalbuminemia affect the process of prescribing?
A) It decreases the free drug concentration, requiring a higher dose
B) It increases the free drug concentration, potentially leading to toxicity
C) It has no effect on drug binding
D) It decreases drug metabolism
Correct Answer: It increases the free drug concentration, potentially leading to
toxicity
Rationale: Hypoalbuminemia reduces the number of protein-binding sites available
for highly protein-bound drugs. This results in a higher fraction of unbound (free)
, drug, which is pharmacologically active, increasing the risk of toxicity and requiring a
lower dose.
5. A patient with a CYP2C19 mutation is prescribed a medication metabolized by this
enzyme. What is the most likely outcome?
A) Increased drug efficacy
B) Increased risk of adverse effects or decreased efficacy depending on the mutation
type
C) No change in drug response
D) Immediate allergic reaction
Correct Answer: Increased risk of adverse effects or decreased efficacy depending
on the mutation type
Rationale: CYP2C19 polymorphisms can result in poor, intermediate, or rapid
metabolizer phenotypes. Poor metabolizers are at risk for toxicity, while rapid
metabolizers may experience therapeutic failure. Genetic testing can guide dosing to
optimize therapy and minimize adverse effects.
6. Which drug is known to auto-induce its own metabolism, requiring careful
monitoring and dose adjustments over time?
A) Warfarin
B) Carbamazepine
C) Levothyroxine
D) Metformin
Correct Answer: Carbamazepine
